Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

European Journal of Heart Failure

Volumn 7, Issue 4, 2005, Pages 650-656

  O'Meara, Eileen ^a   Lewis, Eldrin ^b   Granger, Chris ^c   Dunlap, Mark E ^d   McKelvie, Robert S ^e   Probstfield, Jeffrey L ^f   Young, James B ^g   Michelson, Eric L ^h   Ostergren, Jan ⁱ   Carlsson, Jonas ^j   Olofsson, Bertil ^j   McMurray, John ^a   Yusuf, Salim ^k   Swedberg, Karl ^l   Pfeffer, Marc A ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e HAMILTON GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF WASHINGTON   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h ASTRAZENECA   (United Kingdom)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j ASTRAZENECA R AND D   (Sweden)

^k Ontario Canada   (Canada)

^l SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Angiotensin receptor blockers; Functional capacity; Heart failure; Quality of life; Symptoms

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SPIRONOLACTONE;

ADULT; AGE DISTRIBUTION; AGED; ANALYTIC METHOD; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; HEALTH PROGRAM; HEALTH STATUS; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PERCEPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 19544383364     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2005.01.021     Document Type: Article

References (17)

1. E. O'Meara, S.D. Solomon, J.J.V. McMurray, M. Pfeffer, S. Yasuf, and E. Michelson Effect of candesartan on New York Heart Association functional class. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme Eur Heart J 25 21 2004 Nov 1920 1926
2. J.A. Bennett, B. Riegel, V. Bittner, and J. Nichols Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease Heart Lung 31 2002 262 270
3. A. Hjalmarson, S. Goldstein, B. Fagerberg, H. Wedel, F. Waagstein, and J. Kjekshus Effects of controlled-release metoprolol in total mortality, hospitalizations, and well-being in patients with heart failure JAMA 283 2000 1295 1302
4. D. Fischer, A.L. Stewart, D.A. Bloch, K. Lorig, D. Laurent, and I. Holman Capturing the patient's view of change as a clinical outcome measure JAMA 282 1999 1157 1162
5. V. Strand, S. Cohen, B. Crawford, J.S. Smolen, D.L. Scott Leflunomide Investigators Groups Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis Rheumatology 43 2004 640 647
6. C.B. Granger, J.J. McMurray, S. Yusuf, P. Held, E.L. Michelson, B. Olofsson CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
7. J.J. McMurray, J. Ostergren, K. Swedberg, C.B. Granger, P. Held, E.L. Michelson CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
8. S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
9. M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, E.L. Michelson CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 2003 759 766
10. C.B. Granger, G. Ertl, J. Kuch, A.P. Maggioni, J. McMurray, and J.L. Rouleau Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors Am Heart J 139 2000 609 617
11. J. McMurray, J. Östergren, M. Pfeffer, K. Swedberg, C. Granger, and P. Yasu Held Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme Eur J Heart Fail 5 2003 261 270
12. E.F. Juniper, G.H. Guyatt, A. Willan, and L.E. Griffith Determining a minimal important change in a disease-specific quality of life questionnaire J Clin Epidemiol 47 1994 81 87
13. M. Packer, W.S. Colucci, J.D. Sackner-Bernstein, C.S. Liang, D.A. Goldscher, and I. Freeman Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial Circulation 94 1996 2793 2799
14. W.S. Colucci, M. Packer, M.R. Bristow, E.M. Gilbert, J.N. Cohn, and N. Fowler Congestive heart failure/myocardial disease: carvedilol inhibits clinical progression in patients with mild symptoms of heart failure Circulation 94 1996 2800 2806
15. M.R. Bristow, E.M. Gilbert, W.T. Abraham, K.F. Adams, M.B. Fowler, and R.E. Hershberger Congestive heart failure/myocardial disease: carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure Circulation 94 1996 2807 2816
16. J.N. Cohn, M.D. Fowler, and M.R. Bristow Safety and efficacy of carvedilol in severe heart failure. The U.S. carvedilol heart failure study group J Card Fail 3 1997 173 179
17. A.P. Bolger, and F. Al-Nasser Beta-blockers for chronic heart failure: surviving longer but feeling better? Int J Cardiol 92 2003 1 8